SK bioscience

SK bioscience is dedicated to advancing human health through innovative biotechnology research, spanning prevention to cure. With a proven track record, SK bioscience successfully developed South Korea's first COVID-19 vaccine, 'SKYCovione,' through collaborations with global entities such as the Bill & Melinda Gates Foundation, CEPI, and GSK. The company also pioneered the world's first quadrivalent cell-cultured influenza vaccine, SKYCellflu, achieving WHO PQ certification in 2019, followed by SKYZoster, the world's second shingles vaccine, and SkyVaricella, the world's second WHO PQ-certified chickenpox vaccine.

Located at 경기도 성남시 분당구 판교로 310 (삼평동 686) 판교, KR, SK bioscience is strategically expanding its R&D pipeline through global partnerships with public and private institutions. The company plans to commercialize a pneumococcal conjugate vaccine, cervical cancer vaccine, typhoid conjugate vaccine, and rotavirus vaccine, further solidifying its commitment to global health. SK bioscience also has a CMO contract to manufacture AstraZeneca's COVID-19 vaccine at its L-House vaccine manufacturing plant, contributing significantly to global vaccine production and distribution.

SK bioscience continues to build trust as a global innovative partner in vaccines and biotechnology, striving to meet the expectations of its employees, customers, shareholders, and local communities. To ensure you receive the most current and comprehensive details about SK bioscience's advancements, the company's management is actively updating our platform. We invite the SK bioscience team to create a customized and exclusive company showcase and product listing on our platform to highlight their groundbreaking work.